Summary
Neurotoxicity is a well-recognized and commonly observed side effect associated with the use of vincristine sulfate in cancer chemotherapy. The clinical manifestations of vincristine neuropathy cover a wide spectrum of peripheral neurologic dysfunctions that have been described to be reversible and cumulative in most instances (1, 2). Paresthesias, loss of tendon reflexes, and progressive weakness are the most common clinical features (3, 4). Sensory impairment, cranial nerve palsies, gastrointestinal disturbances, and autonomie dysfunctions including atonic bladder, impotence, and orthostatic hypotension may occur (5). Acute CNS complications, usually presenting as generalized seizures, are extremely rare and only a few cases have been reported which were without underlying biochemical or structural abnormalities (1, 5–9). We describe the case of a woman with multiple myeloma, who developed fulminant encephalopathy following 4 days of continuous vincristine, adriamycin, and day 1–4 pulse dexamethasone (VAD) combination therapy.
Similar content being viewed by others
References
Hardisty RM, McElwain TJ, Darby CW: Vincristine and prednisone for the induction of remissions in acute childhood leukemia. Br Med J 2:662–665, 1969
Panoff A: Pathogenesis of epileptiform seizures in acute leucosis in childhood. Arch Kinderheilkd 183:62–68, 1971
Bradley WG, Lassman L, Pearce GW, Walton JN: The neuropathy of vincristine in man: clinical, electrophysiological and pathological studies. J Neurol Sci 10:107–131, 1970
Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, Shnider BI, Lynch JJ, Owens A, Carbone PP, Colsky J, Grob D, Miller SP, Hall TC: Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33:1258–1264, 1973
Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 18:127–133, 1974
Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr: Seizures associated with vincristine sulfate therapy. J Pediatr 82:699–702, 1973
Jürgenssen OA, Pichler E: Zerebelläre Vincristin-Toxizität. Klin Pädiatr 188:455–458, 1976
Mubashir BA, Bart JB: Vincristine neurotoxicity. N Engl J Med 287:517, 1972
Dallera F, Gamoletti R, Costa P: Unilateral seizures following vincristine intravenous injection. Tumori 70:243–244, 1984
Ludwig H, Fritz E: Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony-forming stem cells. Anticancer Res 1:329–334, 1981
Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356, 1984
Maida EM: Liquorproteinprofile bei entzündlichen Erkran-kungen des Nervensystems. W. Maudrich, Wien-MünchenBern, 1984, p 44
Slater M, Wainer RA, Serpick AA: Vincristine neurotoxicity with hyponatremia. Cancer 23:122–125, 1969
Robertson GL, Bhoopalam N, Zelkowitz LJ: Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 132:717–720, 1973
Fine RN, Clarke RR, Shore NA: Hyponatremia and vincristine therapy. Am J Dis Child 112:256–259, 1966
Suskind RM, Brusilow SW, Zehr J: Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level). J Pediatr 81:90–92, 1972
Shelanski ML, Wisniewski H: Neurofibrillary degeneration induced by vincristine therapy. Arch Neurol 20:199–206, 1969
Burdman JA: A note on the selective toxicity of vincristine sulfate on chickembryo sensory ganglia in tissue culture. J Natl Cancer Inst 37:331–335, 1966
Finkel HE: Vincristine therapy. NY J Med 67:2474–2478, 1967
Weiden PL, Wright SE: Vincristine neurotoxicity. N Engl J Med 286:1369–1370, 1972
Hildebrand J, Kenis Y: Additive toxicity of vincristine and other drugs for the peripheral nervous system. Acta Neurol Bel 71:486–491, 1971
Jones B, Holland JF: Optimal use of asparaginase in acute lymphocytic leukemia of childhood. (Abstract). Blood 42:1015, 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheithauer, W., Ludwig, H. & Maida, E. Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Invest New Drugs 3, 315–318 (1985). https://doi.org/10.1007/BF00179439
Issue Date:
DOI: https://doi.org/10.1007/BF00179439